Patient-informed design supported rapid and representative COMPPARE trial accrual
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Adaptation would have improved organ sparing or target coverage in 46% of fractions, with a median workflow time of 61.9 minutes.
Different carbon-ion RBE models can assign substantially different biological doses to the same absorbed-dose distribution, requiring context-specific translation.
A 1 mm symmetric MLC closing reduced minimum GTV dose by 25%, while translations caused cumulative target undercoverage.
A 1 cm high-density bolus overcame 6 MV photon build-up, but a 2 cm air gap reduced small-field skin dose by 21%.
TLD-100 over-responded below 7 Gy/s and under-responded above 300 Gy/s, despite remaining dose-independent from 3 to 18 Gy.
A dual-input MRI–CT model segmented 25 neurological organs with a median Dice score of 0.80 and surface Dice of 0.84.
Pelvic insufficiency fractures occurred in 29.2% of patients, with postmenopause and elevated baseline t-PINP independently predicting risk.
A structured sleep protocol enabled sedation-free delivery in 96.4% of radiotherapy fractions among children younger than four years.
An MTV threshold of 50 mL identified patients with poorer survival who appeared to benefit from combined-modality treatment.
Proton therapy produced greater CT-detected lung changes than photons despite lower lung dose and no increase in clinical pulmonary toxicity.
Two-year invasive recurrence fell from 27.5% to 5.5% with dose escalation, without higher grade 2 or greater toxicity.
Only 33% of statements reached consensus, but experts agreed on multimodality imaging, eligible lesions, and daily image guidance.
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
Radiographic brain injury occurred in 16% of children, all asymptomatic; every affected patient had received high-dose chemotherapy.